This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghamande, S. Articles by Repasky, E. A Search for Related Content PubMed PubMed Citation Articles by Ghamande, S. Articles by Repasky, E. A

Recombinant CD40 Ligand Therapy Has Significant Antitumor Effects on CD40-positive Ovarian Tumor Xenografts Grown in SCID Mice and Demonstrates an Augmented Effect with Cisplatin¹

Departments of Surgery, Division of Gynecologic Oncology [S. G., S. L.] and Immunology [B. L. H., E. O., E. A. R.], Roswell Park Cancer Center, Buffalo, New York 14263, and Immunex Corporation, Seattle Washington [W. F.]

CD40 is a member of the tumor necrosis factor receptor family and was first identified with a monoclonal antibody raised against bladder carcinoma. Recombinant human CD40L has been shown previously to have a direct antitumor effect on an ovarian cancer cell line and ovarian carcinoma cells isolated from ascites fluid. We show here that rhuCD40L inhibits the growth of several ovarian adenocarcinomas derived from surgical specimens and grown as xenografts in severe combined immunodeficient mice. Two 14-day treatment cycles were more effective than one. This effect is apparently not mediated by natural killer cells, because blocking natural killer cell activity by antiasialo GM-1 did not diminish this effect. In addition to suppression of tumor growth, treatment with rhuCD40L resulted in an increased expression of FasL, an increase in apoptosis, and histological changes including increased fibrosis and areas of tumor destruction. Using this model, we examined the efficacy of rhuCD40L in combination with chemotherapeutic agents. The antitumor effect of rhuCD40L in combination with 4 mg/kg cisplatin (CDDP) was increased over the effect of CDDP alone. Furthermore, rhuCD40L increased the efficacy of a suboptimal dose of CDDP (2mg/kg) such that it matched that of high-dose CDDP alone. These data suggest a role for rhuCD40L therapy in combination with platinum based regimens for primary treatment of epithelial ovarian tumors.

This article has been cited by other articles:

				R. H. Vonderheide Prospect of Targeting the CD40 Pathway for Cancer Therapy Clin. Cancer Res., February 15, 2007; 13(4): 1083 - 1088. [Abstract] [Full Text] [PDF]

				G. Murugaiyan, R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha Functional Dichotomy in CD40 Reciprocally Regulates Effector T Cell Functions J. Immunol., November 15, 2006; 177(10): 6642 - 6649. [Abstract] [Full Text] [PDF]

				C. C. Davies, T. W. Mak, L. S. Young, and A. G. Eliopoulos TRAF6 Is Required for TRAF2-Dependent CD40 Signal Transduction in Nonhemopoietic Cells Mol. Cell. Biol., November 15, 2005; 25(22): 9806 - 9819. [Abstract] [Full Text] [PDF]

				S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al. Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis J. Immunol., January 1, 2005; 174(1): 41 - 50. [Abstract] [Full Text] [PDF]

				C. C. Davies, J. Mason, M. J. O. Wakelam, L. S. Young, and A. G. Eliopoulos Inhibition of Phosphatidylinositol 3-Kinase- and ERK MAPK-regulated Protein Synthesis Reveals the Pro-apoptotic Properties of CD40 Ligation in Carcinoma Cells J. Biol. Chem., January 9, 2004; 279(2): 1010 - 1019. [Abstract] [Full Text] [PDF]

				N. Belousova, N. Korokhov, V. Krendelshchikova, V. Simonenko, G. Mikheeva, P. L. Triozzi, W. A. Aldrich, P. T. Banerjee, S. D. Gillies, D. T. Curiel, et al. Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells J. Virol., November 1, 2003; 77(21): 11367 - 11377. [Abstract] [Full Text] [PDF]

				T. Hakkarainen, A. Hemminki, A. V. Pereboev, S. D. Barker, C. K. Asiedu, T. V. Strong, A. Kanerva, J. Wahlfors, and D. T. Curiel CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses Clin. Cancer Res., February 1, 2003; 9(2): 619 - 624. [Abstract] [Full Text] [PDF]

				U. Bugajska, N. T. Georgopoulos, J. Southgate, P. W. M. Johnson, P. Graber, J. Gordon, P. J. Selby, and L. K. Trejdosiewicz The Effects of Malignant Transformation on Susceptibility of Human Urothelial Cells to CD40-Mediated Apoptosis J Natl Cancer Inst, September 18, 2002; 94(18): 1381 - 1395. [Abstract] [Full Text] [PDF]